Belite Bio, Inc EV/FCF LTM
| Dec'22 | Dec'23 | |
|---|---|---|
| EV/FCF LTM | 1.1x | (214.1x) |
Belite Bio, Inc (BLTE) EV/FCF LTM comparison analysis
General
LTM EV/FCF LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
BLTE key stats
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.2 | 0.4 |
% margin | (0.0) 0.0% | (0.0) 0.0% | (0.2) 0.0% | (0.4) 0.0% |
| Operating Expenses | 5.7 | 9.8 | 12.8 | 31.7 |
| Research & Development Expenses (R&D) | 3.7 | 7.4 | 8.9 | 24.8 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 4.0 | 6.8 |
% margin | (5.7) 0.0% | (9.8) 0.0% | (12.8) 0.0% | (31.7) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (5.8) | (9.7) | (12.6) | (31.6) |
% effective tax rate | 0.0 (0.0%) | 0.1 (1.3%) | (0.2) 1.4% | 0.0 (0.0%) |
% margin | (5.8) 0.0% | (9.8) 0.0% | (12.5) 0.0% | (31.6) 0.0% |
| EPS | (0.24) | (0.41) | (0.62) | (1.19) |
| Diluted EPS | (0.24) | (0.41) | (0.62) | (1.19) |
% margin | (5.7) 0.0% | (9.6) 0.0% | (12.4) 0.0% | (31.5) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Belite Bio, Inc's EV/FCF LTM?
As of today, Microsoft Corp's last 12-month EV/FCF LTM is N/A, based on the financial report for Sep 27, 2024 (Q3’2024). The average annual EV/FCF LTM for Belite Bio, Inc have been (81.1x) over the past three years, and (60.8x) over the past five years.
2) Is Belite Bio, Inc's EV/FCF LTM Good?
As of today, Belite Bio, Inc's EV/FCF LTM is N/A, which is N/A than industry median of (0.6x). It indicates that Belite Bio, Inc's EV/FCF LTM is undefined.